Global mRNA cancer vaccines and therapeutics market is poised for substantial growth, projected to rise from USD 185 million in 2025 to USD 556 million by 2031, exhibiting an impressive CAGR of 20.6% during the forecast period. Valued at USD 155 million in 2024, the market’s rapid expansion underscores the increasing adoption of mRNA technology in oncology, driven by advancements in precision medicine, immunotherapy, and biotechnology innovation.
The growing global burden of cancer, coupled with the success of mRNA platforms in infectious diseases, has accelerated their transition into oncology applications. These therapies offer high specificity, rapid development potential, and adaptability — key factors enhancing their acceptance across research institutions, hospitals, and biotech companies worldwide.
Claim a Free Insight Sample https://www.24lifesciences.com/download-sample/6294/mrna-cancer-vaccines-and-therapeutics-market-market
Market Highlights: Segmentation and Growth Drivers
The mRNA cancer vaccines and therapeutics market is segmented by type, application, and end user, reflecting its diverse clinical and commercial landscape.
By Type
- Individualized Neoantigen Vaccines
- Shared Antigen Vaccines
- Combination Therapies
The individualized neoantigen vaccine segment dominates due to its personalized approach in targeting patient-specific tumor mutations. This innovation aligns with the broader healthcare shift toward precision oncology, enabling improved immunogenicity and treatment efficacy.
By Application
- Solid Tumors
- Hematological Malignancies
- Prevention & Prophylaxis
- Combination Therapies
Solid tumor treatments represent the largest application segment, driven by ongoing clinical trials evaluating mRNA vaccines for melanoma, lung, and pancreatic cancers. The hematological malignancy segment is also gaining traction due to breakthroughs in combination therapies that integrate mRNA platforms with checkpoint inhibitors and targeted agents.
By End User
- Academic & Research Institutes
- Biotechnology Companies
- Hospitals & Cancer Centers
Biotechnology companies hold a leading position in the market, supported by strong R&D investments and strategic partnerships with academic institutions. Hospitals and cancer centers are increasingly adopting these therapies as clinical trials move toward late-phase development and commercial readiness.
Key Market Drivers
Several factors are propelling the market forward:
- Rising cancer prevalence: Global cancer incidence continues to rise, creating urgent demand for more effective, personalized therapies.
- mRNA technology maturity: The success of mRNA-based COVID-19 vaccines has validated this platform’s scalability and safety, accelerating oncology research applications.
- Regulatory support and funding: Growing investments in immuno-oncology and government-backed R&D initiatives are enhancing innovation pipelines.
- Shift toward personalized medicine: The evolution of genomic sequencing and bioinformatics enables customized mRNA therapies tailored to individual cancer profiles.
Emerging Trends Shaping the Healthcare Market
The integration of artificial intelligence (AI), digital health platforms, and data analytics is redefining how oncology innovations are developed and delivered. AI is being utilized for neoantigen prediction, optimizing vaccine design, and improving patient response tracking. Meanwhile, advances in RNA stabilization, nanoparticle delivery systems, and combination immunotherapies are driving next-generation cancer vaccine formulations.
Moreover, the rise of decentralized clinical trials and digital biomarker monitoring is accelerating the pace of global cancer vaccine research. These trends collectively position the mRNA therapeutics market as a key frontier in precision oncology and biopharmaceutical development.
Key Players and Competitive Landscape
Prominent players driving the mRNA cancer vaccines and therapeutics market include:
- BioNTech SE (Germany)
- Moderna Inc. (USA)
- Translate Bio (USA)
- CureVac N.V. (Germany)
- eTheRNA Immunotherapies (Belgium)
- Gritstone Bio Inc. (USA)
These companies are leveraging their mRNA expertise through strategic collaborations, product pipeline expansions, and advanced clinical trials. Key competitive strategies include partnerships with oncology research centers, AI-driven vaccine design, and advancements in lipid nanoparticle delivery technologies.
Explore the Full Market Report https://www.24lifesciences.com/mrna-cancer-vaccines-and-therapeutics-market-market-6294
Long-Term Vision
The future of the mRNA cancer vaccines and therapeutics market appears highly promising. As clinical trials mature and regulatory approvals accelerate, mRNA platforms are expected to revolutionize cancer care by enabling faster, safer, and more personalized treatment options. The market’s expected growth to USD 556 million by 2031 at a 20.6% CAGR reflects this transformative potential.
With growing investments in mRNA oncology pipelines, integration of AI technologies, and rising demand for personalized immunotherapies, the coming decade is set to witness unprecedented advancements in cancer vaccine therapeutics.
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: www.24lifesciences.com
Follow us on LinkedIn: www.linkedin.com/company/lifesciences24
- Single-Domain Heavy Chain Antibody Market - 2026-01-23
- Qianlie Antong Capsules Market - 2026-01-23
- Veterinary Amitraz Solution Market - 2026-01-23